- Home
- PPBT vs BCLI Comparison
PPBT vs BCLI Comparison
Compare PPBT & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- BCLI
- Stock Information
- Founded
- PPBT 2010
- BCLI 2000
- Country
- PPBT Israel
- BCLI United States
- Employees
- PPBT N/A
- BCLI N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PPBT Health Care
- BCLI Health Care
- Exchange
- PPBT Nasdaq
- BCLI Nasdaq
- Market Cap
- PPBT 8.7M
- BCLI 9.9M
- IPO Year
- PPBT N/A
- BCLI N/A
- Fundamental
- Price
- PPBT $3.17
- BCLI $1.73
- Analyst Decision
- PPBT Strong Buy
- BCLI Strong Buy
- Analyst Count
- PPBT 2
- BCLI 1
- Target Price
- PPBT $126.50
- BCLI $30.00
- AVG Volume (30 Days)
- PPBT 23.2K
- BCLI 41.1K
- Earning Date
- PPBT 03-07-2025
- BCLI 03-31-2025
- Dividend Yield
- PPBT N/A
- BCLI N/A
- EPS Growth
- PPBT N/A
- BCLI N/A
- EPS
- PPBT N/A
- BCLI N/A
- Revenue
- PPBT N/A
- BCLI N/A
- Revenue This Year
- PPBT N/A
- BCLI N/A
- Revenue Next Year
- PPBT N/A
- BCLI N/A
- P/E Ratio
- PPBT N/A
- BCLI N/A
- Revenue Growth
- PPBT N/A
- BCLI N/A
- 52 Week Low
- PPBT $2.00
- BCLI $1.05
- 52 Week High
- PPBT $20.60
- BCLI $11.85
- Technical
- Relative Strength Index (RSI)
- PPBT 44.15
- BCLI 40.62
- Support Level
- PPBT $3.01
- BCLI $1.69
- Resistance Level
- PPBT $3.48
- BCLI $1.93
- Average True Range (ATR)
- PPBT 0.22
- BCLI 0.11
- MACD
- PPBT 0.03
- BCLI -0.00
- Stochastic Oscillator
- PPBT 52.63
- BCLI 16.67
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.